These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33109706)

  • 1. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
    Al-Chalabi A; Chiò A; Merrill C; Oster G; Bornheimer R; Agnese W; Apple S
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):165-171. PubMed ID: 33109706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
    Gebrehiwet P; Meng L; Rudnicki SA; Sarocco P; Wei J; Wolff AA; Chiò A; Andrews JA; Genge A; Jackson CE; Lechtzin N; Miller TM; Shefner JM
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):304-310. PubMed ID: 36503310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the King's and MiToS staging systems for ALS.
    Fang T; Al Khleifat A; Stahl DR; Lazo La Torre C; Murphy C; ; Young C; Shaw PJ; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):227-232. PubMed ID: 28054828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the ability of the King's and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis.
    Luna J; Couratier P; Lahmadi S; Lautrette G; Fontana A; Tortelli R; Logroscino G; Preux PM; Copetti M; Benoit M
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 Nov; 22(7-8):478-485. PubMed ID: 33829938
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
    Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
    Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
    Takahashi F; Takei K; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
    [No Abstract]   [Full Text] [Related]  

  • 9. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of ALS staging systems in a multi-ethnic patient cohort.
    Abdul Aziz NA; Toh TH; Loh EC; Capelle DP; Goh KJ; Abdul Latif L; Chung TY; Shahrizaila N
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 Aug; 22(5-6):341-349. PubMed ID: 33726578
    [No Abstract]   [Full Text] [Related]  

  • 11. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.
    Thakore NJ; Lapin BR; Kinzy TG; Pioro EP
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):483-494. PubMed ID: 30001159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
    Takei K; Tsuda K; Takahashi F; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
    Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
    PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study.
    Ferraro D; Consonni D; Fini N; Fasano A; Del Giovane C; ; Mandrioli J
    Eur J Neurol; 2016 Sep; 23(9):1426-32. PubMed ID: 27238551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.
    He R; Zheng M; Lian L; Yao X
    Cells; 2021 May; 10(5):. PubMed ID: 34067647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
    Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.